通过CRISPR/Cas9基因组编辑打破乳腺癌成瘾性

Yang Haitao, Jaeger MariaLynn, Walker Averi, Wei Daniel, Leiker Katie, Weitao Tao

Laboratory for Cancer Genome Editing, Zhuhai Lifecode Medical Technologies. Inc. Department of Prenatal Diagnosis, Huizhou 2nd Hospital for Children and Women, #101 University Road, Tangjiawan, Zhuhai, 518900, Guangdong, China.

College of Science and Mathematics, Southwest Baptist University, 1600 University Avenue, Bolivar, Missouri 65613, USA.

J Cancer. 2018 Jan 1;9(2):219-231. doi: 10.7150/jca.22554. eCollection 2018.

Breast cancer is the leading diagnosed cancer for women globally. Evolution of breast cancer in tumorigenesis, metastasis and treatment resistance appears to be driven by the aberrant gene expression and protein degradation encoded by the cancer genomes. The uncontrolled cancer growth relies on these cellular events, thus constituting the cancerous programs and rendering the addiction towards them. These programs are likely the potential anticancer biomarkers for Personalized Medicine of breast cancer. This review intends to delineate the impact of the CRSPR/Cas-mediated genome editing in identification and validation of these anticancer biomarkers. It reviews the progress in three aspects of CRISPR/Cas9-mediated editing of the breast cancer genomes: Somatic genome editing, transcription and protein degradation addictions.

乳腺癌是全球女性中诊断出的最常见癌症。乳腺癌在肿瘤发生、转移和治疗耐药性方面的演变似乎是由癌症基因组编码的异常基因表达和蛋白质降解所驱动的。不受控制的癌症生长依赖于这些细胞事件，从而构成了癌性程序并导致对它们的依赖。这些程序可能是乳腺癌个性化医疗的潜在抗癌生物标志物。本综述旨在阐述CRISPR/Cas介导的基因组编辑在这些抗癌生物标志物的鉴定和验证中的作用。它回顾了CRISPR/Cas9介导的乳腺癌基因组编辑在三个方面的进展：体细胞基因组编辑、转录和蛋白质降解依赖性。